| Trial ID # | NCT01633970 |
| Phase | Ib |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Atezolizumab, Bevacizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 20 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 15% (3PR, n=20) |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Bevacizumab+atezolizumab induces durable responses and/or disease stabilization in some patients with platinum-resistant ovarian cancer; the safety profiles are consistent with those of each agent |
| Reference | Moroney JW et al. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res (2020) 26(21):5631-5637 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.